BriaCell Therapeutics ( (TSE:BCT) ) has provided an update.
BriaCell Therapeutics announced a significant clinical response in the first patient treated with their Bria-OTS™ immunotherapy, showing complete resolution of lung metastasis from metastatic breast cancer after only two months of treatment. This outcome highlights the potential of Bria-OTS™ as a new and effective treatment option for metastatic breast cancer, offering hope for patients who have not responded to other therapies. The ongoing Phase 1/2a study aims to further evaluate the treatment’s efficacy and safety.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. The company’s primary product, Bria-OTS™, is a personalized off-the-shelf immunotherapy currently under investigation for treating metastatic breast cancer.
YTD Price Performance: -40.49%
Average Trading Volume: 5,412
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$21.31M
See more insights into BCT stock on TipRanks’ Stock Analysis page.